5-Amino-1MQ Complete Research Guide 2026
5-Amino-1MQ is a small-molecule NNMT inhibitor studied for its effects on cellular NAD+ metabolism, adipocyte function, and metabolic regulation. Unlike peptide compounds, it is an orally bioavailable small molecule — making it a distinct and increasingly researched tool in metabolic science.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme with significant roles in cellular metabolism, NAD+ homeostasis, and adipocyte biology. Its mechanism is mechanistically distinct from the peptide compounds that dominate metabolic research, making it a valuable complementary research tool for investigating cellular energy metabolism.
NNMT — The Target Enzyme
Nicotinamide N-methyltransferase catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine. This reaction is significant for two reasons relevant to metabolic research. First, it consumes nicotinamide — a precursor in the NAD+ salvage pathway — potentially diverting it away from NAD+ regeneration. Second, it consumes SAM, the universal methyl donor, affecting cellular methylation capacity broadly.
NNMT expression is elevated in the adipose tissue and liver of metabolically dysfunctional research models. This elevated expression has been characterized as contributing to metabolic dysregulation through both NAD+ depletion and altered cellular methylation status — making NNMT an attractive target for metabolic research intervention.
Mechanism of 5-Amino-1MQ
5-Amino-1MQ inhibits NNMT enzymatic activity, preventing the methylation of nicotinamide. The research-documented consequences of this inhibition include preservation of the cellular nicotinamide pool for NAD+ salvage, increased cellular NAD+ availability, and preservation of SAM for other cellular methylation reactions. The net effect in research models is enhanced cellular energy metabolism and altered adipocyte function.
Adipocyte Research
The most studied application of 5-Amino-1MQ involves adipocyte biology. Published research documented that NNMT inhibition in adipocytes increases cellular energy expenditure and promotes lipolysis. In research models, NNMT knockdown or pharmacological inhibition with 5-Amino-1MQ was associated with protection against diet-induced obesity and improved metabolic parameters. The mechanism appears to involve the restoration of NAD+-dependent sirtuin activity in adipocytes, driving increased mitochondrial activity and fat oxidation.
NAD+ Connection
5-Amino-1MQ represents a mechanistically distinct approach to NAD+ research compared to direct NAD+ precursor supplementation (NMN, NR). Rather than supplying additional NAD+ precursors, 5-Amino-1MQ preserves the existing nicotinamide pool by preventing its methylation-mediated removal. This makes it a complementary research tool for studying NAD+ metabolism — investigating the salvage pathway from the angle of precursor preservation rather than precursor supplementation. Research combining NNMT inhibition with NAD+ precursor supplementation is an active area of metabolic investigation.
Oral Bioavailability — A Research Advantage
Unlike the peptide compounds common in metabolic research, 5-Amino-1MQ is a small molecule with oral bioavailability. This characteristic makes it particularly useful for research models requiring oral administration and for studies where the practical limitations of injectable peptide administration would complicate the experimental design. Its small-molecule nature also provides defined, reproducible pharmacology valuable for mechanistic research.
5-Amino-1MQ — Available for Research COA-verified, USA-synthesized. For laboratory and research use only. View Catalog
Research Use Only. Research Use Disclaimer5-Amino-1MQ is a research compound intended for laboratory use only. Not for human consumption. For research use only per Ares Research terms.
Related Research Articles
Best Peptide Stack for Summer Cut Research 2026
Summer is when "cut" research protocols see peak demand — simultaneous fat mass reduction and muscle preservation is the most searched body composition research goal from June through August. Here's the mechanistically justified summer research stack.
Retatrutide vs Tirzepatide — Which Is Better for Research in
This is the most searched GLP-class comparison right now. The honest answer isn't "one is better" — it's that they're better at different research questions. Here's the definitive mechanistic breakdown and the decision framework for choosing between them.
Best Research Peptides for Body Recomposition
Body recomposition research — fat loss and muscle preservation simultaneously — requires compounds from at least two distinct mechanistic categories. Here's the optimal summer 2026 research design combining GLP-class and GH-axis compounds for the complete recomposition picture.
Best Peptides for Weight Loss Research
The metabolic research peptide landscape has a clear evidence hierarchy — from the most mature Phase 3 data to emerging Phase 2 findings. Here's how each major compound ranks by evidence strength, mechanism complexity, and what makes it distinct for fat mass research.
Semaglutide Weight Loss Plateau Research 2026
Weight loss on GLP-1 agonists typically plateaus after 24-36 weeks — a finding documented across the STEP trial program. Understanding why this happens mechanistically, and what the research shows about progression strategies, is among the most clinically relevant questions in the class.
Visceral Fat Research and Peptides 2026 — GLP, Tesamorelin,
Visceral adipose tissue — metabolically active fat surrounding abdominal organs — is documented as more metabolically consequential than subcutaneous fat, making it a specific research target for several compound categories through distinct mechanisms.
Neutral, moderated research discussion. Laboratory use only.
More compound guides, hubs, and educational research materials.